Diagnosis

Global Experts Tackle Infection Risks in Multiple Myeloma, Call for Unified Prevention Guidelines

In patients with multiple myeloma, infection is the primary cause of morbidity and mortality, influenced by a combination of the disease itself, treatments, and individual patient factors. The...
CURATED BY: Laura J. Zitella,
MS, RN, ACNP-BC, AOCN
Picture of Laura J. Zitella
Laura J. Zitella
MS, RN, ACNP-BC, AOCN
Nurse Practitioner in Hematology/Oncology, University of California San Francisco
Read More

Lenalidomide: Observation in Smoldering Multiple Myeloma

Intervening early with lenalidomide for multiple myeloma (MM) could delay progression to symptomatic disease. ...
CURATED BY:
Larisa A. Gallo,
DMSc, PA-C
Read More >

The Latest on COVID-19 for Multiple Myeloma Patients

The International Myeloma Foundation recommends patients first learn about COVID-19 symptoms, and then know how to check their community’s level of the virus. Monitoring for symptoms is essential, as is and...
CURATED BY:
Larisa A. Gallo,
DMSc, PA-C
Read More >

Minimal Residual Disease Negativity in Multiple Myeloma

Researchers conducted a large-scale pooled analysis for associations between patients achieving complete response or better with MRD-negative status and progression-free survival. ...
CURATED BY:
Larisa A. Gallo,
DMSc, PA-C
Read More >

Current and Future Treatment of Multiple Myeloma

Dr. Ken Anderson discusses current and future treatments for multiple myeloma during Dana-Farber Cancer Institute’s 2020 Multiple Myeloma Patient Symposium....
CURATED BY:
Larisa A. Gallo,
DMSc, PA-C
Read More >

Risk Stratification Model for Smoldering Multiple Myeloma

A study with 1996 patients with smoldering multiple myeloma (SMM) established a risk stratification system to predict progression to multiple myeloma (MM) within two years. Three key factors – serum...
CURATED BY:
Jill N. Burke,
CNP, DipACLM
Read More >

Myeloma Bone Disease: From Biology Findings to Treatment Approaches

Researchers analyzed the critical role osteocytes play in the development of myeloma bone disease (MBD), a major complication in multiple myeloma (MM). Osteocytes contribute to increased osteoclast activity, reduced osteoblast...
CURATED BY:
Jill N. Burke,
CNP, DipACLM
Read More >
Load More

Privacy Policy
Terms of Use

Company
Contact

Partner with Us
Ambassador Program

© 2024 Point of Care Network, LLC. All Rights Reserved.

Privacy Policy
Terms of Use
Company
Contact
Partner with Us
Ambassador Program

© 2022 Point of Care Network, LLC. All Rights Reserved.

Share